### Supplementary Table 5. Multiple Cox regression analysis for risk factors influencing occurrence of renal dysfunction after liver transplantation

| Variable                           | Univariate                  | Multivariate               |
|-----------------------------------|-----------------------------|----------------------------|
|                                   | HR (95% CI) | P-value | HR (95% CI) | P-value |
| Recipients’ age                   | 1.03 (1.02, 1.03) | <0.001 | 1.28 (1.19, 1.38) | <0.001 |
| Donors’ age                       | 1.01 (1.00, 1.01) | 0.001 |              |         |
| Male recipient                    | 0.71 (0.62, 0.81) | <0.001 | 1.03 (0.90, 1.18) | 0.679 |
| Male donor                        | 1.04 (0.91, 1.19) | 0.541 |              |         |
| Recipients’ BMI ≥25 (kg/m^2)      | 1.05 (0.89, 1.25) | 0.512 |              |         |
| Donors’ BMI ≥25 (kg/m^2)          | 1.12 (0.93, 1.34) | 0.225 |              |         |
| LDLT vs. DDLT                     | 0.62 (0.54, 0.71) | <0.001 | 0.79 (0.67, 0.93) | 0.004 |
| Hypertension                      | 1.34 (1.14, 1.56) | <0.001 | 1.25 (1.06, 1.47) | 0.007 |
| Diabetes mellitus                 | 1.32 (1.15, 1.52) | <0.001 | 1.20 (1.04, 1.39) | 0.011 |
| MELD score: ≥35                   | 2.26 (1.73, 2.95) | <0.001 | 1.81 (1.47, 2.23) | <0.001 |
| HCC                               | 0.70 (0.61, 0.79) | <0.001 |              |         |
| Acute hepatitis                   | 1.27 (0.86, 1.89) | 0.227 | 1.06 (0.78, 1.44) | 0.695 |
| ABO incompatible                   | 1.46 (1.20, 1.78) | <0.001 |              |         |
| Use of steroids                    | 0.77 (0.64, 0.93) | 0.007 | 0.82 (0.67, 0.99) | 0.040 |
| Use of anti-metabolites            | 0.78 (0.68, 0.89) | <0.001 |              |         |
| Use of mTOR inhibitors             | 0.92 (0.76, 1.12) | 0.412 |              |         |

HR, hazards ratio; CI, confidence interval; BMI, body-mass index; LDLT, living donor liver transplantation; DDLT, deceased donor liver transplantation; MELD, Model for End-Stage Liver Disease; HCC, hepatocellular carcinoma; mTOR, mammalian target of rapamycin.